Clinical Trials Logo

Heart Transplant Rejection clinical trials

View clinical trials related to Heart Transplant Rejection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06064123 Recruiting - Clinical trials for Heart Transplant Rejection

Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation

EMBIO
Start date: January 22, 2019
Phase:
Study type: Observational [Patient Registry]

The objective of this prospective observational single center study is to investigate donor-derived cell-free DNA (ddcfDNA), peripheral blood platelet mRNA, peripheral blood extracellular vesicle mRNA, and peripheral blood leukocyte mRNA expression in recognition of clinically significant endomyocardial biopsy (EMB) proven acute rejection in human heart transplant recipients. In detail, the objective is to develop novel biomarkers and liquid biopsies for diagnosis, prognosis, and targeted molecular therapy for primary graft failure, ischemia-reperfusion injury, acute rejection, and development of late graft failure and cardiac allograft vasculopathy, and for monitoring immunosuppression after heart transplantation.

NCT ID: NCT04973943 Recruiting - Clinical trials for Heart Transplant Rejection

Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection

FreeDNA-CAR
Start date: March 19, 2019
Phase:
Study type: Observational

FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain. Our main objective is to test donor-derived Cell-Free DNA (dd-cfDNA) against endomyocardial biopsy (EMB) for the diagnosis of acute cellular rejection.

NCT ID: NCT04707872 Recruiting - Clinical trials for Heart Transplant Rejection

Trifecta-Heart cfDNA-MMDx Study

Start date: June 1, 2021
Phase:
Study type: Observational

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.

NCT ID: NCT04226521 Recruiting - Clinical trials for Cardiac Allograft Vasculopathy

Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy

ECP-OCT
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV). This posttransplant complication develops slowly over several years, and when diagnosed either by conventional coronary angiography or due to graft failure, it is often too advanced and difficult to treat since it is diffuse coronary artery disease. Therefore, early prevention of CAV is a subject of major interest in the transplant cardiology. Since CAV is associated with immune factors, immunomodulatory therapeutic options, like extracorporeal photopheresis are lately being investigated. Unlike conventional coronary angiography, optical coherence tomography (OCT) is able to detect the development of CAV in the earliest phase, i.e. even in the first post-transplant year. In our study, we plan to investigate the prophylactic effect of extracorporeal photopheresis in the early development of cardiac graft vasculopathy detected by OCT.